Posted from: Friday, December 01, 2017 - 01:38 PM - Present

Cinvanti Approved to Prevent Chemotherapy-Induced Nausea

November 9, 2017 – The U.S. FDA has approved Cinvanti™ (aprepitant) injectable emulsion, manufactured by Heron Therapeutics, as an antiemetic to prevent chemotherapy-induced nausea and vomiting (CINV) in adult patients who are receiving treatment with chemo drugs that present a moderate or high risk of CINV. Administered as an intravenous infusion, Cinvanti is to be used in conjunction with a corticosteroid and a serotonin-3 (5-HT3) receptor inhibitor, such as ondansetron.

Cinvanti is a substance P/neurokinin-1 (NK1) receptor antagonist. This type of drug works by blocking certain receptor sites in the brain. Cinvanti can be used to prevent both acute and delayed episodes of CINV. Recommended dosing is 130mg if the chemo drugs being used are associated with a high risk of CINV, and 100mg for drugs that present only a moderate risk. In both cases, Cinvanti is administered as a 30-minute infusion approximately half an hour before the administration of chemotherapy.

Launch of the drug is expected in January 2018.


Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by U.S. mail or by fax.

Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.


Last Updated Monday, September 16, 2019 - 09:29 PM.